373 related articles for article (PubMed ID: 31036879)
1. Rational design of anti-GITR-based combination immunotherapy.
Zappasodi R; Sirard C; Li Y; Budhu S; Abu-Akeel M; Liu C; Yang X; Zhong H; Newman W; Qi J; Wong P; Schaer D; Koon H; Velcheti V; Hellmann MD; Postow MA; Callahan MK; Wolchok JD; Merghoub T
Nat Med; 2019 May; 25(5):759-766. PubMed ID: 31036879
[TBL] [Abstract][Full Text] [Related]
2. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
Mahne AE; Mauze S; Joyce-Shaikh B; Xia J; Bowman EP; Beebe AM; Cua DJ; Jain R
Cancer Res; 2017 Mar; 77(5):1108-1118. PubMed ID: 28122327
[TBL] [Abstract][Full Text] [Related]
3. Rationale for anti-GITR cancer immunotherapy.
Knee DA; Hewes B; Brogdon JL
Eur J Cancer; 2016 Nov; 67():1-10. PubMed ID: 27591414
[TBL] [Abstract][Full Text] [Related]
4. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
5. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.
Schaer DA; Budhu S; Liu C; Bryson C; Malandro N; Cohen A; Zhong H; Yang X; Houghton AN; Merghoub T; Wolchok JD
Cancer Immunol Res; 2013 Nov; 1(5):320-31. PubMed ID: 24416730
[TBL] [Abstract][Full Text] [Related]
6. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.
Schoenhals JE; Cushman TR; Barsoumian HB; Li A; Cadena AP; Niknam S; Younes AI; Caetano MDS; Cortez MA; Welsh JW
Front Immunol; 2018; 9():2170. PubMed ID: 30294332
[TBL] [Abstract][Full Text] [Related]
7. Modulation of tumor immunity: a patent evaluation of WO2015026684A1.
Nocentini G; Cari L; Ronchetti S; Riccardi C
Expert Opin Ther Pat; 2016; 26(3):417-25. PubMed ID: 26560753
[TBL] [Abstract][Full Text] [Related]
8. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
[TBL] [Abstract][Full Text] [Related]
9. Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.
Villarreal DO; Chin D; Smith MA; Luistro LL; Snyder LA
Oncotarget; 2017 Jun; 8(24):39117-39130. PubMed ID: 28388572
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness.
Hirschhorn D; Betof Warner A; Maniyar R; Chow A; Mangarin LM; Cohen AD; Hamadene L; Rizzuto GA; Budhu S; Suek N; Liu C; Houghton AN; Merghoub T; Wolchok JD
JCI Insight; 2021 Oct; 6(20):. PubMed ID: 34676831
[TBL] [Abstract][Full Text] [Related]
11. A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
Leyland R; Watkins A; Mulgrew KA; Holoweckyj N; Bamber L; Tigue NJ; Offer E; Andrews J; Yan L; Mullins S; Oberst MD; Coates Ulrichsen J; Leinster DA; McGlinchey K; Young L; Morrow M; Hammond SA; Mallinder P; Herath A; Leow CC; Wilkinson RW; Stewart R
Clin Cancer Res; 2017 Jul; 23(13):3416-3427. PubMed ID: 28069723
[No Abstract] [Full Text] [Related]
12. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
van Beek AA; Zhou G; Doukas M; Boor PPC; Noordam L; Mancham S; Campos Carrascosa L; van der Heide-Mulder M; Polak WG; Ijzermans JNM; Pan Q; Heirman C; Mahne A; Bucktrout SL; Bruno MJ; Sprengers D; Kwekkeboom J
Int J Cancer; 2019 Aug; 145(4):1111-1124. PubMed ID: 30719701
[TBL] [Abstract][Full Text] [Related]
13. Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma.
Scirka B; Szurek E; Pietrzak M; Rempala G; Kisielow P; Ignatowicz L; Miazek A
Arch Immunol Ther Exp (Warsz); 2017 Dec; 65(6):553-564. PubMed ID: 28638937
[TBL] [Abstract][Full Text] [Related]
14. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy.
Yang R; Sun L; Li CF; Wang YH; Yao J; Li H; Yan M; Chang WC; Hsu JM; Cha JH; Hsu JL; Chou CW; Sun X; Deng Y; Chou CK; Yu D; Hung MC
Nat Commun; 2021 Feb; 12(1):832. PubMed ID: 33547304
[TBL] [Abstract][Full Text] [Related]
15.
Wang B; Zhang W; Jankovic V; Golubov J; Poon P; Oswald EM; Gurer C; Wei J; Ramos I; Wu Q; Waite J; Ni M; Adler C; Wei Y; Macdonald L; Rowlands T; Brydges S; Siao J; Poueymirou W; MacDonald D; Yancopoulos GD; Sleeman MA; Murphy AJ; Skokos D
Sci Immunol; 2018 Nov; 3(29):. PubMed ID: 30389797
[TBL] [Abstract][Full Text] [Related]
16. Targeting GITR in cancer immunotherapy - there is no perfect knowledge.
Davar D; Zappasodi R
Oncotarget; 2023 Jun; 14():614-621. PubMed ID: 37335294
[TBL] [Abstract][Full Text] [Related]
17. An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy.
Chan S; Belmar N; Ho S; Rogers B; Stickler M; Graham M; Lee E; Tran N; Zhang D; Gupta P; Sho M; MacDonough T; Woolley A; Kim H; Zhang H; Liu W; Zheng P; Dezso Z; Halliwill K; Ceccarelli M; Rhodes S; Thakur A; Forsyth CM; Xiong M; Tan SS; Iyer R; Lake M; Digiammarino E; Zhou L; Bigelow L; Longenecker K; Judge RA; Liu C; Trumble M; Remis JP; Fox M; Cairns B; Akamatsu Y; Hollenbaugh D; Harding F; Alvarez HM
Nat Cancer; 2022 Mar; 3(3):337-354. PubMed ID: 35256819
[TBL] [Abstract][Full Text] [Related]
18. Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells.
Sukumar S; Wilson DC; Yu Y; Wong J; Naravula S; Ermakov G; Riener R; Bhagwat B; Necheva AS; Grein J; Churakova T; Mangadu R; Georgiev P; Manfra D; Pinheiro EM; Sriram V; Bailey WJ; Herzyk D; McClanahan TK; Willingham A; Beebe AM; Sadekova S
Cancer Res; 2017 Aug; 77(16):4378-4388. PubMed ID: 28611044
[TBL] [Abstract][Full Text] [Related]
19. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD
PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651
[TBL] [Abstract][Full Text] [Related]
20. New emerging targets in cancer immunotherapy: the role of GITR.
Buzzatti G; Dellepiane C; Del Mastro L
ESMO Open; 2020 Aug; 4(Suppl 3):e000738. PubMed ID: 32817129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
